Cantor Fitzgerald Believes Amneal Pharmaceuticals Inc (AMRX) Won’t Stop Here


In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amneal Pharmaceuticals Inc (NYSE: AMRX), with a price target of $35. The company’s shares closed on Friday at $21.52, close to its 52-week high of $22.41.

Chen wrote:

“We rate AMRX as 12-month price target of $35. We believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA analysis to arrive at our $35 PT.”

According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -5.6% and a 39.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amneal Pharmaceuticals Inc with a $25.17 average price target, implying a 17.0% upside from current levels. In a report issued on August 9, B.Riley FBR also assigned a Buy rating to the stock with a $26 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $22.41 and a one-year low of $13.47. Currently, Amneal Pharmaceuticals Inc has an average volume of 1.09M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts